רווח תפעולי לפני ניכוי פחת: Pharvaris (PHVS)

Pharvaris N.V. (PHVS) maintains a resilient business driven by protected capital and cost control, as evidenced by its financial EBITDA. The 0.00 level represents the current value of this curve. The company develops innovative tablets for the therapy of hereditary angioedema, targeting the orphan drug segment. Lars Nibel's strategic direction ensures a high level of scientific readiness for the future market launch of the drug.

The monetization of innovative tablets for the treatment of HAE forms the primary cash flow for Pharvaris N.V. (PHVS). This figure is calculated by excluding depreciation, taxes, and interest expenses from operating profit. The metric reflects the business's actual ability to generate cash, independent of accounting conventions. The trend in annual EBITDA serves as an indicator of the company's fundamental stability. Analysis of this chart allows for an assessment of the drug's commercialization efficiency regardless of the debt load.